Clinical trials: Hypertension
Erectile Dysfunction
Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension
The purpose of this study is to evaluate the efficacy and safety of SK3530 in men with ED and hypertension who were taking antihypertensive medication.
- Trial name
- NCT00644007
- Testing
- SK3530
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- SK Chemicals Co., Ltd.
Hypertension, Dyslipidemia
Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population
The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
- Trial name
- CAPABLE (NCT00150384)
- Testing
- Amlodipine/Atorvastatin
- Where
- 106 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, MTHFR 677 CC or CT Genotype
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
This is a multi-center, randomized, double-blind, double-dummy, controlled clinical trial. This trial will include 32,000 Chinese men and women with hypertension (H-type hypertension), MTHFR 677 CC or CT genotype, elevated plasma…
- Conditions
- Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
- Trial name
- CSPPT2-CC/CT (NCT04974138)
- Testing
- Amlodipine besylate, Amlodipine besylate and folic acid
- Where
- 20 sites in China
- Volunteers
- 32,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Pre-hypertension
A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults
This study will investigate the effect of a nitric oxide supplementation product, Neo40 Daily®, on blood pressure in pre-hypertensive and mildly hypertensive adults.
- Trial name
- 15NBHN (NCT02679248)
- Testing
- Neo40 Daily®
- Where
- 2 sites in Canada
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Pulmonary Arterial Hypertension
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
- Trial name
- NCT00423748
- Testing
- ambrisentan
- Volunteers
- 186 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Adult Congenital Heart Disease Registry (QuERI)
Multi-center, observational, U.S.-based longitudinal program. Data will be collected prospectively for 3 years. Individual physician feedback will be provided on data collected with the purpose of improving the management of…
- Trial name
- NCT01659411
- Testing
- Observational
- Volunteers
- 217 people
- Sponsor
- Actelion
Hypertension
Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension
The purpose of this extension study is to compare the long-term safety of valsartan versus enalapril, and the effectiveness of the combination of valsartan and enalapril versus enalapril alone in children with hypertension.
- Trial name
- NCT00446511
- Testing
- Valsartan, Enalapril
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 250 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 150/5 mg is superior to that of amlodipine 5 mg monotherapy in lowering systolic blood pressure (SBP) as measured…
- Trial name
- I-COMBINE (NCT00956644)
- Testing
- irbesartan/amlodipine, amlodipine
- Where
- 40 sites in Brazil, Chile and 7 more
- Volunteers
- 406 people
- Sponsor
- Sanofi
Hypertension
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
- Trial name
- KARDIA-2 (NCT05103332)
- Testing
- Indapamide, Amlodipine, Olmesartan
- Where
- 110 sites in United States, Canada and 6 more
- Volunteers
- 663 people
- Sponsor
- Alnylam Pharmaceuticals
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
The purpose of this study is to investigate the effect of Atorvastatin on the pharmacokinetic properties of Telmisartan/S-amlodipine
- Trial name
- CKD-345 DDI (NCT01842230)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, Telmisartan 80mg and S-amlodipine 5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension,Essential
A Study to Evaluate the Efficacy and Safety of AD-224
The purpose of this study is to evaluate the efficacy and safety of AD-224
- Trial name
- NCT06291207
- Testing
- AD-224A, AD-224B, AD-224C
- Where
- South Korea
- Volunteers
- 254 people
- Sponsor
- Addpharma Inc.
Hypertension
Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure
The purpose of this 12-week active controlled trial is to evaluate the safety and efficacy of valsartan 80/160/320 mg (weight stratified) compared with enalapril 10/20/40 mg (weight stratified) on sitting systolic blood pressure…
- Trial name
- NCT00433836
- Testing
- Valsartan, Enalapril
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
This is a multinational, multi center extension study. This study will provide data on the long-term safety, tolerability, and efficacy of imatinib in the treatment of severe pulmonary arterial hypertension.
- Trial name
- IMPRES Extn (NCT01117987)
- Testing
- Imatinib
- Where
- 59 sites in United States, Austria and 11 more
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
High Cardiovascular Risk, Hypertension
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
- Trial name
- KARDIA-3 (NCT06272487)
- Testing
- Zilebesiran
- Where
- 195 sites in United States, Australia and 4 more
- Volunteers
- 375 people
- Sponsor
- Alnylam Pharmaceuticals
Glaucomas, Pterygium
Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Zhong-Shan Hospital
The purpose of this study is to determine whether the OculusGen Collagen Matrix are effective and safe to implant as an aid of glaucoma surgery.
- Trial name
- NCT00320957
- Testing
- OculusGen Biodegradable Collagen Matrix Implant
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Pro Top & Mediking Company Limited
Hypertension, Diabetes Mellitus, Type 2
Proteus Discover in Subjects With Uncontrolled Hypertension and Type 2 Diabetes
The purpose of this study was to evaluate the efficacy of a new digital health offering, Proteus Discover to lower blood pressure and glycated hemoglobin in patients with uncontrolled hypertension and type 2 diabetes.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Hypercholesterolemia
- Trial name
- NCT02827630
- Testing
- Proteus Discover, Usual Care
- Volunteers
- 118 people
- Sponsor
- Proteus Digital Health, Inc.
Hypertension
A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg
The purpose of this was to evaluate valsartan 320mg compared to valsartan 160 mg in terms of blood pressure reduction in a patient population of mild to moderate hypertensives
- Trial name
- NCT00241137
- Testing
- valsartan
- Where
- Germany
- Volunteers
- 3,790 people, healthy volunteers welcome
- Sponsor
- Novartis
Hypertension
A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)
This study will determine if MK-3614, given as single doses, is safe and well tolerated in healthy males and male participants with mild to moderate hypertension.
- Trial name
- NCT01104545
- Testing
- MK-3614
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Hypertension
Monitoring Subjects With Fluid-Management Issues In the Home Environment
This study is designed to validate ease-of-use for the CoVa Monitoring System, along with simple statistical parameters such as reproducibility and inter-subject agreement between test and reference devices.
- Trial name
- NCT02190877
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Baxter Healthcare Corporation
Hypertension, Hypertension,Essential
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
- Trial name
- NCT06205628
- Testing
- ADX-850
- Where
- 3 sites in Australia
- Volunteers
- 28 people
- Sponsor
- ADARx Pharmaceuticals, Inc.